S6 Ep4: Diabetes Affects CRC Outcomes, Vitamin D May Prevent Neuropathy

<div>The end of the year typically brings a number of FDA approvals, and 2023 is no different. Last week, the Food and Drug Administration approved a new drug, Augyro (repotrectinib) for the treatment of patients with ROS1-positive non-small cell lung cancer. <br> <br> </div> <br> <div>Also making oncology headlines this week, is an expert update on the cancer drug shortage, research about how the severity of diabetes can impact colorectal cancer outcomes and how vitamin D may be able to mitigate the severity of chemotherapy-induced peripheral neuropathy. <strong><br>  <br> <br> </strong><br> <a href="https://www.curetoday.com/view/fda-approves-augtyro-for-patients-with-nsclc-subset"><strong>FDA Approves Augtyro for Patients With NSCLC Subset<br> </strong></a><br> </div> <br> <div>Another week, another FDA approval. This time, the agency approved Augtyro for the treatment of patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer. <br> <br> </div> <br> <div>The drug works by targeting ROS1 oncogene fusions, which can be responsible for the growth of cancer. The approval was based off findings from the phase 1/2 TRIDENT-1 clinical trial, which showed that 79% of patients responded to therapy with the drug, including 6% who experienced a complete response, which is when all signs of cancer disappear. <br> <br> </div> <br> <div>Bristol Myers Squibb, the pharmaceutical company that manufacturers Augtyro, expects the drug to be available to patients in mid-December. <br> <br> </div> <br> <br> <div> <a href="https://www.curetoday.com/view/fda-approves-keytruda-plus-chemo-for-advanced-her2-negative-gastric-gej-cancers"><strong>FDA Approves Keytruda plus Chemo for Advanced HER2-Negative Gastric, GEJ Cancers<br> </strong></a><br> </div> <br> <div>Also in FDA news last week, the agency approved the immunotherapy drug, Keytruda, in combination with chemotherapy for the treatment of patients with advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenoca